Background: The optimal treatment for advanced heart failure (HF) patients with regards to mortality remains unknown. Heart transplantation (HTx) and left ventricular assist devices (LVAD) used either as a bridge to transplant (BTT) or destination therapy (DT) have been compared in a number of studies, without definite conclusions with regards to mortality benefit. We sought to systematically review the pertinent literature and perform a meta-analysis of all the available studies presenting head-to-head comparisons between HTx and LVAD BTT or LVAD DT for late (>6 months) all-cause mortality.
Introduction
Heart failure (HF) is a significant cause of morbidity and mortality that increases healthcare costs and leads to worsened quality of life, with a prevalence close to 23 million worldwide (1) (2) (3) (4) . Despite improvements in survival deriving from better medical therapies and prevention of sudden cardiac death, a percentage of patients with progressive HF continue to require heart transplantation (HTx) or durable mechanical support [e.g., left ventricular assist devices (LVAD)] to prolong life (5) . HTx remains the gold standard for end stage heart disease in adults. However, because of the paucity of donor hearts and the multiple common contraindications, this option is available only for a small fraction of patients (6, 7) . A ventricular assist device (VAD) is a type of durable mechanical circulatory support that partially replaces the function of the failing © Annals of Cardiothoracic Surgery. All rights reserved.
Ann Cardiothorac Surg 2018;7(1):3-11 www.annalscts.com heart. Use of LVADs has grown steadily over the past decade since their initial approval for use as a bridge-totransplantation (BTT). Second and third generation LVADs have achieved improved durability through the use of wear free components, allowing for the upgrading of LVAD use to a destination therapy (DT) strategy in patients who are ineligible for HTx (8) . LVADs provide patients with significant clinical improvement and prolong survival but are not free of complications (9) . Data on 1-year mortality for patients managed with HTx vs. LVAD (BTT or DT) have been published by a number of observational, real world studies. Despite that, there is no clear evidence so far on the superiority of one of these strategies. With this systematic review and meta-analysis, we synthesize in a qualitative and quantitative manner all the available studies that present a head to head comparison between HTx and LVAD DT or HTx and LVAD BTT. Our aim is to reach informative conclusions regarding the potential superiority of one of the two strategies with regards to 1-year survival.
Methods
This systematic review and meta-analysis was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (10) .
Literature search and eligibility criteria
Medline and Cochrane Central databases were reviewed by two reviewers independently (Christina A. Theochari and George Michalopoulos) for relevant articles published until February 28, 2017 . The Medline algorithm used was the following: (VAD OR BiVAD OR LVAD OR ventricle-assist device OR "ventricle assist device" OR "ventricular assist device" OR "heart-assist device" OR "heart assist device" OR "heart-assist pump" OR "heart assist pump" OR "ventricular-assist device" OR "artificial ventricle" OR "mechanical circulatory support" ) AND ("heart transplantation" OR "heart grafting" OR "cardiac transplantation" OR "heart transplant" OR "cardiac transplant") AND ("heart failure" OR "myocardial failure" OR "cardiac failure" OR "heart decompensation").
The following inclusion criteria were used: (I) observational studies (real-world studies); (II) studies published in any language; (III) studies published up to February 28, 2017 ; (IV) studies presenting head to head comparisons between HTx and LVAD DT and/or HTx and LVAD BTT for HF patients; (V) studies that reported outcomes for one-year mortality. A study was considered eligible for the meta-analysis if fulfilled all the inclusion criteria. When there was a disagreement between the two reviewers (Christina A. Theochari and George Michalopoulos), a third reviewer (Evangelos Oikonomou) was involved in order to reach consensus. References from all the included studies and other relevant review papers were also manually reviewed in order to identify potentially additional eligible studies.
Data extraction and quality assessment
Data extraction from the eligible studies was performed by two investigators (Christina A. Theochari and George Michalopoulos) independently. Any disagreements were resolved by consensus. A standardized extraction form in an Excel spreadsheet was used. Data for the following variables were extracted: first author; year of publication; country and center; setting; study design and methodology; patient demographic characteristics (gender, age, race); HF etiology; LVAD strategy (BTT or DT); index hospitalization length; follow-up length after the primary intervention; readmission rate per year of support, stroke, infections, cost and mortality. The primary outcome of our meta-analysis was late mortality (>6 months). The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the observational studies included in our metaanalysis. The NOS has two different instruments for assessing case-control and cohort studies. Each instrument includes measures of quality in three domains: selection, comparability, and exposure. A study can receive up to one point for each of four areas measured within the selection domain and for each of three areas measured within the exposure domain. A maximum of two points can be assigned within the comparability domain. The highest possible score is nine. High-quality studies were considered to have a score of seven or greater. Study quality was assessed independently by two investigators (Christina A. Theochari and George Michalopoulos).
Statistical analysis
In order to calculate the risk estimates within each study for patients treated with HTx, LVAD DT or LVAD BTT, we extracted the absolute number of patients who had an event in each arm. For studies that reported only relative and not absolute frequencies, we used the total number of eligible patients in each arm to calculate the absolute frequencies of the events. Categorical variables are presented as absolute and relative frequencies and continuous variables as mean values ± SD. The estimated incidence rates were expressed as percentage and 95% confidence intervals (CI). A random effects model was used for our meta-analysis. Heterogeneity among studies was assessed with the I 2 statistic. Values <25% indicated non-significant heterogeneity, 25% to 50% indicated moderate, and >50% indicated severe heterogeneity. Forest plots were used to present the overall effects. Both of our analyses included less than 10 studies (five studies for HTx vs. LVAD DT, and seven studies for HTx vs. LVAD BTT) while by definition the included studies were observational and not randomized controlled trials. We used funnel plots in an attempt to locate possible publication bias, despite the small number of the available studies for each outcome ( Figure S1A ,B) (10, 11) . The results were regarded as statistically significant at a two-sided P<0.05. We used STATA 14.1 (StataCorp, College Station, Texas, USA) as statistical software.
Results
Our searches yielded 2,760 studies from Medline and 93 from Cochrane Central. After removal of duplicates, we assess for eligibility 2,849 studies. We excluded 2,809 studies based on their title and abstract and 40 articles were retrieved for full-text review, before resulting in the eight eligible studies (11) (12) (13) (14) (15) (16) (17) (18) . The detailed flow diagram is presented in Figure 1 . All studies were deemed to be of high quality on the basis of the NOS score; two were assessed with 9 stars, three with 8 stars and three with 7 stars. Our meta-analysis showed that there was no significant difference in 1-year mortality rates between these two groups (pooled OR: 0.91; 95% CI: 0.62-1.32) (Figure 2) , without significant heterogeneity (I 2 =21.2). Comparison data between HTx and LVAD DT, were reported by five studies. Our meta-analysis showed absence of significant differences in 1-year mortality rates also between these two groups (pooled OR: 1.49; 95% CI: 0.48-4.66) (Figure 3) , although the heterogeneity was significant here (I 2 =82.8).
Stroke and infection rates were reported by four studies. Stroke rates ranged from 0% to 4.3% in the HTx group, from 0% to 6.1% in the LVAD BTT group and from 4.3% to 6.1% in the LVAD DT group. Infection rates ranged from 0.5% to 25.5% in the HTx group, from 21.1% to 26.5% in the LVAD DT group and from 0% to 32.6% in the LVAD BTT patients. The total cost per patient was reported by three studies for the HTx group (range: 128,474 to 230,009 USD), by three studies for the LVAD BTT group (range: 95,428 to 166,415 USD) and by one study for the LVAD DT group (range: 152,931 to 174,165 USD).
Discussion
To the best of our knowledge, this is the first systematic review and meta-analysis on this topic. We included only studies presenting head to head comparisons between HTx and LVAD. We used the available data to perform two different and clinically meaningful comparisons: HTx vs. LVAD DT and HTx vs. LVAD BTT. Our findings show that there was no difference in 1-year mortality rates between LVAD BTT and HTx (pooled OR: 0.91; 95% CI: 0.62-1.32; I 2 =21.2%) or between LVAD DT and HTx (pooled OR: 1.49; 95% OR: 0.48-4.66; I 2 =82.8%).
Previous published observational studies agreed with our results and indicated that there is not a statistically significant difference in 1-year mortality between HTx and BTT LVAD patients not only for 1-year mortality but also for early (30-day) or 2-and 5-year mortality. There is only one observational study (Attisani et al.) that supports a HTx superiority for in-hospital mortality (14) . This last study compared patients on the waiting list for HTx with urgent conditions and patients managed with LVAD as a BTT. In-hospital mortality was found to be significantly higher for HTx waiting list patients compared to BTT LVAD patients (42.3% vs. 4.3%, P=0.002). Although almost all of the included studies, similarly to our overall results, did not find statistically significant differences in 1-year mortality between DT LVAD and HTx patients, Mishra et al. found that DT LVAD patients had inferior short term survival comparing to HTx (17) . However, this study was limited by its small size. Although complications with LVAD therapy are not uncommon, most of them are manageable and current outcomes clearly support the use of LVAD in advanced HF (19, 20) . On the other hand, HTx remains a promising treatment option for many patients but suitable donor availability remains extremely limited (21) . There are important distinctions to be made between candidates for each treatment. For instance, pulmonary hypertension is a significant contraindication for transplantation but not for LVAD therapy (22) . In contrast, patients with severe right ventricular failure are less optimal candidates for LVAD, but may experience good outcomes with transplantation (23) (24) (25) (26) . With regards to renal dysfunction, current data show that LVAD implantation can lead to an improvement (27) . On the other hand, LVAD is not a panacea and there are multiple subgroups of patients who have contraindications for LVAD implantation, including those prone to infection, elderly patients and patients with untreated aortic regurgitation (28) (29) (30) (31) . Furthermore, LVAD implantation may be associated with increased tendency to ventricular tachyarrhythmia (32) . Whether a distinction between BTT and DT patients is clinically meaningful, remains a questionable issue (33) . There is a possibility that patients awaiting transplantation on LVAD support may develop contraindications to transplant, or never receive a suitable organ given the paucity of donors (24) .
Limitations
This was a meta-analysis of real-world data and should thus be interpreted within the context of the known limitations of the observational research. Retrospective studies are associated with bias and endpoints for LVAD and HTx may not be directly comparable. In the absence of additional data, we included a small number of studies and patients with heterogeneous populations at baseline. Without knowing specific patient level characteristics of the included studies, we were unable to adjust for comorbidities and other baseline characteristics. Furthermore, the LVAD type was not the same in all the individual studies. In some studies, patients who were initially managed as BTT were converted to DT LVAD, either due to the paucity of available heart transplant, or other inhibitory conditions. This overlap limited our ability to clearly differentiate these two groups of patients. Last but not least, our funnel plots are not able to totally exclude or confirm publications bias, since they are limited by the small number of studies. Publication bias can be suspected, considering that research teams were less likely to publish insignificant or negative findings for the one or the other approach.
Conclusions
Despite the limitations, this systematic review and metaanalysis qualitatively and quantitatively synthesized the published evidence comparing the 1-year survival between HTx and LVAD either as bridge to transplantation or destination therapy. Both LVAD strategies seem to be noninferior to HTx. Unique limitations to each treatment strategy are likely to continue to dictate patient eligibility for each therapy in the absence of clear survival benefit differences. We anticipate that with the addition of more real-world data in the future, safer conclusions could be reached on this important clinical topic.
